# OnCo record neuroblastoma-low-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/neuroblastoma-low-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "neuroblastoma-low-risk" ;
  schema:name "Low-risk neuroblastoma (INRG very low and low risk, including stage MS)"@en ;
  schema:alternateName "Very low-risk neuroblastoma"@en, "Stage MS neuroblastoma"@en, "Stage 4S neuroblastoma"@en, "Localised neuroblastoma in infants"@en ;
  schema:description "Low-risk neuroblastoma is the form found in infants and young children whose tumour has not spread beyond its site or, in the special stage MS pattern, has spread only to the liver, skin and a little marrow. Many of these tumours shrink and disappear on their own, so treatment is surgery, or simply watching, and almost every child survives."@en ;
  schema:url <https://onco.cc/cancers/neuroblastoma-low-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroblastoma>, <https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/neuroblastoma-intermediate-risk/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/mri/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:terms <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/segmental-chromosomal-aberrations/>, <https://onco.cc/terms/urinary-catecholamines/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-inrg-cohn-jco-2009/>, <https://onco.cc/key-papers/paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012/>, <https://onco.cc/key-papers/paper-p9641-low-risk-neuroblastoma-strother-jco-2012/> ;
  onco:pipeline <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://onco.cc/technologies/ultrasound/> ;
  onco:standardOfCare <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/terms/late-effects/> .